All manuscripts
Publications CTL Cells G-Rex®10

SOP: D03.31.22 INITIATION OF EBV- OR ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL)

Published

Share
12 pages SOP: D03.31.22 INITIATION OF EBV- OR ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES (CTL) — 2011

Overview

SOP for initiating CTLs. Describes initiating cells in '24-well plate or GRex40 '. Details seeding 1x10^7 cells in 5mL for G-Rex®40 and culturing for 9 days for initial stimulation

What this paper found

This GMP standard operating procedure describes how to start cytotoxic T cell lines specific for Epstein-Barr virus or for a chosen antigen from patient or donor blood cells. Responder PBMC are stimulated at 2 × 10^6 cells per mL with irradiated autologous lymphoblastoid cells at a 40:1 ratio, or with adenovirus-transduced dendritic cells or monocytes. Cultures grow in 24-well plates or in a GRex40 bioreactor, which holds 1 × 10^7 PBMC and is brought to 30 mL, for 7 to 9 days. A second stimulation follows on days 9 to 12, provided viability exceeds 60%, and IL-2 is then added at 50 to 100 units per mL. The SOP also gives a worked dose calculation.

Under the culture conditions employed, outgrowing T cell lines should contain T cells specific for the antigen of interest. — Cliona Rooney, Oumar Diouf, Malcolm Brenner, Adrian Gee

Study details

Authors
Cliona Rooney, Oumar Diouf, Malcolm Brenner, Adrian Gee
Institution
Center for Cell & Gene Therapy, GMP Facility, Feigin Center, Houston, Texas, USA
Year
2011
G-Rex® model(s)
G-Rex®10
Cell type(s)
CTL Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

For EBV-specific CTL initiation, 5 mL of responder PBMC (1 × 10^7 cells, resuspended at 2 × 10^6 cells per mL) is placed in a GRex40 bioreactor as an alternative to a 24-well plate. Irradiated (40 Gy) autologous LCL at 5 × 10^4 cells per mL are added at a 40:1 PBMC to LCL ratio, as 5 mL per GRex40, and the volume is brought to 30 mL. The GRex40 is cultured at 37°C in 5% CO2 for 9 days, whereas plates are cultured for 7 days. Responder cells are then harvested for the second stimulation, which can also be done in G-Rex® under SOP D03.32.

Explore related

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →